(September 6, 2017, 11:37 AM EDT) -- WASHINGTON, D.C. — Drug maker Novo Nordisk Inc. on Sept. 5 agreed to pay $58.65 million to settle federal allegations that it instructed sales representatives to downplay a federally required warning about the risk of medullary thyroid carcinoma (MTC) from the company’s diabetes drug Victoza (United States of America v. Novo Nordisk, Inc., No. 17-cv-1820, D. D.C.)....